---
layout: default
title: Fluoroestradiol F-18
parent: 僅模型預測 (L5)
nav_order: 721
evidence_level: L5
indication_count: 1
---

# Fluoroestradiol F-18
{: .fs-9 }

證據等級: **L5** | 預測適應症: **1** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fluoroestradiol F-18: From Unrecorded Original Indication to Amenorrhea (Disease)

## One-Sentence Summary

Fluoroestradiol F-18 (DrugBank ID DB15690) has no confirmed original indication or mechanism-of-action data in the current evidence pack, and it is not marketed in the Taiwan/US-tracked market (0 licenses on file). The TxGNN model predicts a possible association with **Amenorrhea (disease)**, but this prediction is currently supported by **0 clinical trials** and **0 publications**, making it a pure computational signal with no independent corroboration.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available — no license or indication text recorded in the evidence pack |
| Predicted New Indication | Amenorrhea (disease) |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L5 (model prediction only, no supporting trials or literature) |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not currently available for Fluoroestradiol F-18, and the evidence pack also contains no record of its original approved indication. Without either piece of information, it is not possible to construct a pharmacological rationale linking the drug's known biological activity to amenorrhea.

It is also worth flagging a signal-quality caveat directly from the data: although the TxGNN prediction score is high (99.40%), the associated **rank is 13,815** — a very low priority position within the model's overall candidate ranking. A high raw score paired with such a low rank suggests this association sits far down the model's prioritized list, and should be interpreted with caution rather than as a strong repurposing lead.

Given the absence of MOA data, original indication data, and any corroborating clinical or literature evidence, no mechanistic argument can currently be made for or against this prediction. This should be treated strictly as an unvalidated computational output pending further data collection.

---

## Clinical Trial Evidence

Currently no related clinical trials registered

---

## Literature Evidence

Currently no related literature available

---

## US Market Information

No license records are currently available — the drug is recorded as **Not Marketed**, with 0 authorizations on file.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate has no supporting clinical trials, no literature evidence, no mechanism-of-action data, and no confirmed original indication — combined with a very low TxGNN rank (13,815) despite the high displayed score, the evidence base is currently insufficient to justify further evaluation or investment.

**To proceed, the following is needed:**
- TFDA label warnings/contraindications (currently a **Blocking** data gap — required before any safety pre-screening, per DG001)
- Mechanism of action (MOA) data via DrugBank API (High priority, per DG002)
- Confirmation of the drug's original approved indication(s)
- At least preclinical or mechanistic literature establishing a plausible link to amenorrhea before considering clinical evidence collection
- Re-evaluation of the TxGNN rank/score discrepancy to confirm this is a genuine high-priority signal rather than a low-priority artifact
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

